<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933489</url>
  </required_header>
  <id_info>
    <org_study_id>EA1141</org_study_id>
    <secondary_id>NCI-2016-00252</secondary_id>
    <secondary_id>s16-01825</secondary_id>
    <secondary_id>EA1141</secondary_id>
    <secondary_id>ECOG-ACRIN-EA1141</secondary_id>
    <secondary_id>EA1141</secondary_id>
    <secondary_id>UG1CA189828</secondary_id>
    <nct_id>NCT02933489</nct_id>
  </id_info>
  <brief_title>Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts</brief_title>
  <official_title>Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women With Dense Breasts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECOG-ACRIN Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well abbreviated breast magnetic resonance imaging&#xD;
      (MRI) and digital tomosynthesis mammography work in detecting cancer in women with dense&#xD;
      breasts. Abbreviated breast MRI is a low cost procedure in which radio waves and a powerful&#xD;
      magnet linked to a computer and used to create detailed pictures of the breast in less than&#xD;
      10 minutes. These pictures can show the difference between normal and diseased tissue.&#xD;
      Digital tomosynthesis mammography is a procedure that uses multiple x-rays pictures of each&#xD;
      breast to produce a 3-dimensional rendering of the entire breast. Combined screening with&#xD;
      abbreviated breast MRI and digital tomosynthesis mammography may be a better method to screen&#xD;
      women with dense breasts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the rates of detection of invasive cancers between the initial abbreviated&#xD;
      breast (AB)-magnetic resonance (MR) and digital tomosynthesis mammography (DBT).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the positive predictive value (PPV) of biopsies, call back rates, and&#xD;
      short-term follow up rates after AB-MR and DBT on both the initial and 1 year follow up&#xD;
      studies.&#xD;
&#xD;
      II. To estimate and compare the sensitivity and specificity of AB-MR and DBT, using the 1&#xD;
      year follow up to define a reference standard.&#xD;
&#xD;
      III. To compare patient-reported short-term quality of life related to diagnostic testing&#xD;
      with AB-MR and DBT using the Testing Morbidities Index.&#xD;
&#xD;
      IV. To compare willingness to return for testing with AB-MRI versus (vs) DBT within the&#xD;
      recommended screening interval and explore factors associated with willingness to return for&#xD;
      screening.&#xD;
&#xD;
      V. To compare the tumor biologies of invasive cancers and ductal carcinoma in situ (DCIS)&#xD;
      detected on AB-MR and DBT.&#xD;
&#xD;
      VI. To estimate the incident cancer rate during 3 years following the year-1 AB-MR/DBT when&#xD;
      patients return to standard screening.&#xD;
&#xD;
      OUTLINE: Participants are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM A (DBT, AB-MR): Participants undergo DBT followed by AB-MR for under 10 minutes on the&#xD;
      same day or within 24 hours at baseline and then after 1 year.&#xD;
&#xD;
      ARM B (AB-MR, DBT): Participants undergo AB-MR for under 10 minutes followed by DBT on the&#xD;
      same day or within 24 hours at baseline and then after 1 year.&#xD;
&#xD;
      After completion of study, patients are followed up at every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 27, 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Actual">January 23, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Screen-detected Invasive Cancer Verified by Pathology</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>For each modality, the detection rate of invasive cancers is defined as the proportion of participants who had an invasive cancer detected by the modality at baseline and verified by pathology versus the total number of participants. In the out come measures table below, these proportions will be automatically calculated, multiplied by 100, and be presented as percentages (%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prediction of Breast Cancer (Sensitivity and Specificity)</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
    <description>Reference standard positive (RS+): breast cancer (invasive or DCIS) detected on the year 0 screening or reported at any time from the year 0 to the year 1 screening.&#xD;
Reference standard negative (RS-): No breast cancer reported at any time from the year 0 to the year 1 screen.&#xD;
Incomplete: No Year 1 imaging, and &lt;11 months of patient follow-up (&lt;330 days) after year 0 screen&#xD;
Positive Test (T+) is defined as the imaging modality result is positive (BI-RADS 3-5), and the location of the finding is matches the location of the cancer indicated by the reference standard.&#xD;
Negative Test (T-) will be estimated as the fraction of reference standard negative subjects for whom the imaging modality result was negative (BI-RADS 1-2).&#xD;
95% confidence intervals for the sensitivity and specificity of each modality calculated using the Wilson method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Predictive Value (PPV) of Biopsies</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
    <description>Test Positive (T+): Biopsy recommended by imaging, defined as patients with at least one lesion rated BI-RADS 4 or 5 on image interpretation. Reference Standard Positive (RS+): Pathologically confirmed DCIS or invasive disease resultant from a positive test.&#xD;
The 95% confidence interval for PPV of biopsy for each modality were derived from the GEE model using the appropriate estimable contrasts with robust standard errors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Call Back/Additional Imaging/Short-term Follow Rates for DBT and AB-MR</measure>
    <time_frame>Baseline</time_frame>
    <description>For DBT:&#xD;
DBT: Call back is defined as having additional views or targeted ultrasound to evaluate DBT findings DBT: short term follow up (STFU) is defined as having at least one lesion rated BI-RADS 3 on DBT DBT: Additional imaging recommendation is defined as having either call back or STFU&#xD;
For AB-MR:&#xD;
Ab-MR: Call back does not apply to AB-MR and will not be evaluated Ab-MR: Short Term Follow-up (STFU) is defined as having at least one lesion rated BI-RADS 3 on AB-MR Ab-MR: Additional imaging recommendation is defined as having a STFU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ductal Carcinoma in Situ (DCIS) Detected on Abbreviated Breast-magnetic Resonance (MR) and Digital Tomosynthesis Mammography (DBT)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The analysis for will be descriptive. If the Oncotype-DCIS score was performed, the distributions of scores will be tabulated and compared.&#xD;
A low risk score is less than 39, and a high risk score is 55 or higher. A score of 39 to 54 is intermediate risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident Cancer Rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Breast cancer incidence will be estimated. Person-years will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Biologies of Invasive Cancers</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The analysis for will be descriptive. The frequencies of cancer types determined by the NanoString analysis will be tabulated and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors Associated With Willingness to Return for Screening</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Polytomous logistic regression will be used to examine factors associated with willingness to return, including screen result, cancer status, and demographic characteristics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-reported Short-term Quality of Life Related to Diagnostic Testing</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
    <description>Separate Testing Morbidities Index (TMI) scores will be computed for abbreviated breast-magnetic resonance (MR) and digital tomosynthesis mammography (DBT) after the baseline screen. Scores will be compared using a nonparametric test that accounts for the pairing of scores by participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Willingness to Return for Testing With Abbreviated Breast-magnetic Resonance (MR) Versus Digital Tomosynthesis Mammography (DBT)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The proportions of participants willing to return for screening with either test, AB-MRI only, DBT only, or not willing to return for either test will be estimated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1516</enrollment>
  <condition>Asymptomatic</condition>
  <arm_group>
    <arm_group_label>Arm A (DBT, AB-MR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo DBT followed by AB-MR for under 10 minutes on the same day or within 24 hours at baseline and then after 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (AB-MR, DBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo AB-MR for under 10 minutes followed by DBT on the same day or within 24 hours at baseline and then after 1year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Contrast-enhanced Magnetic Resonance Imaging</intervention_name>
    <description>Undergo AB-MR</description>
    <arm_group_label>Arm A (DBT, AB-MR)</arm_group_label>
    <arm_group_label>Arm B (AB-MR, DBT)</arm_group_label>
    <other_name>CONTRAST ENHANCED MRI</other_name>
    <other_name>Contrast-enhanced MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Digital Tomosynthesis Mammography</intervention_name>
    <description>Undergo DBT</description>
    <arm_group_label>Arm A (DBT, AB-MR)</arm_group_label>
    <arm_group_label>Arm B (AB-MR, DBT)</arm_group_label>
    <other_name>DBT</other_name>
    <other_name>Digital Breast Tomosynthesis</other_name>
    <other_name>Digital Tomosynthesis of the Breast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A (DBT, AB-MR)</arm_group_label>
    <arm_group_label>Arm B (AB-MR, DBT)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A (DBT, AB-MR)</arm_group_label>
    <arm_group_label>Arm B (AB-MR, DBT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patents must be scheduled for routine screening DBT&#xD;
&#xD;
          -  Women must not be pregnant or breast-feeding; all females of childbearing potential&#xD;
             who are uncertain if they could be pregnant or may be pregnant or as per local site&#xD;
             standard of practice in women undergoing DBT and MRI must have a blood test or urine&#xD;
             study within 2 weeks prior to randomization to rule out pregnancy; a female of&#xD;
             childbearing potential is any woman, regardless of sexual orientation or whether they&#xD;
             have undergone tubal ligation, who meets the following criteria: 1) has not undergone&#xD;
             a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal&#xD;
             for at least 24 consecutive months (i.e., has had menses at any time in the preceding&#xD;
             24 consecutive months)&#xD;
&#xD;
          -  Women of childbearing potential must be strongly advised to use an accepted and&#xD;
             effective method of contraception or to abstain from sexual intercourse for the&#xD;
             following year until the year 1 AB-MR and DBT studies are performed&#xD;
&#xD;
          -  Patient?s breast density must be known; patients must have mammographically dense&#xD;
             breasts, American College of Radiology [ACR] Breast Imaging [BI]- Reporting and Data&#xD;
             System Atlas (RADS) lexicon categories c or d (heterogeneous or extreme fibroglandular&#xD;
             tissue) on their most-recent prior screening&#xD;
&#xD;
          -  Patient must be asymptomatic for breast disease and undergoing routine screening&#xD;
&#xD;
          -  Patient must have no known breast cancer (DCIS or invasive cancer), not currently&#xD;
             undergoing treatment for breast cancer, or planning surgery for a high risk lesion&#xD;
             (atypical ductal breast hyperplasia [ADH], atypical lobular breast hyperplasia [ALH],&#xD;
             lobular breast carcinoma in situ [LCIS], papilloma, radial scar)&#xD;
&#xD;
          -  Patient must not be taking chemoprevention for breast cancer&#xD;
&#xD;
          -  Patient must not have undergone breast ultrasound within 12 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Patient must not have previously had a breast MRI&#xD;
&#xD;
          -  Patient must not have previously had molecular breast imaging (MBI, multiplexed ion&#xD;
             beam imaging [MIBI])&#xD;
&#xD;
          -  Patient must agree to not undergo screening ultrasound (of breast) for the duration of&#xD;
             the 1 year study period&#xD;
&#xD;
          -  Patient must not be suspected of being at high-risk for breast cancer, as defined by&#xD;
             the American Cancer Society (ACS) breast MR screening recommendations (lifetime risk&#xD;
             of &gt;= 20-25%)&#xD;
&#xD;
          -  Patient must be able to undergo breast MRI with contrast enhancement; patients unable&#xD;
             to undergo breast MRI with contrast enhancement for any reason are ineligible&#xD;
&#xD;
               -  No history of untreatable claustrophobia&#xD;
&#xD;
               -  No presence of non MR compatible metallic objects or metallic objects that, in&#xD;
                  the opinion of the radiologist, would make MRI a contraindication&#xD;
&#xD;
               -  No history of sickle cell disease&#xD;
&#xD;
               -  No contraindication to intravenous contrast administration&#xD;
&#xD;
               -  No known allergy-like reaction to gadolinium or moderate or severe allergic&#xD;
                  reactions to one or more allergens as defined by the American College of&#xD;
                  Radiology (ACR); patient may be eligible if willing to undergo pre-treatment as&#xD;
                  defined by the institution's policy and/or ACR guidance&#xD;
&#xD;
               -  No known or suspected renal impairment; requirements for glomerular filtration&#xD;
                  rate (GFR) prior to MRI as determined by local site standard practice&#xD;
&#xD;
               -  Weight less than or equal to the MRI table limit&#xD;
&#xD;
               -  No women who have had prior contrast enhanced mammography (contrast enhanced&#xD;
                  spectral mammography [CESM] or contrast enhanced digital mammography [CEDM])&#xD;
&#xD;
               -  No women who have breast prosthetic implants (silicone or saline) Exclusion&#xD;
                  Criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Comstock</last_name>
    <role>Principal Investigator</role>
    <affiliation>ECOG-ACRIN Cancer Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntington Memorial Hospital</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Women's Imaging Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiology Imaging Associates</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen F Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Center for Women LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem-Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Radiologists SC</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University/Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Community Hospital</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Associates at Mercy Medical Center</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital-Westwood Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center Jefferson</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Saint Mary's</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essentia Health Cancer Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverview Medical Center/Booker Cancer Center</name>
      <address>
        <city>Red Bank</city>
        <state>New Jersey</state>
        <zip>07701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center-Einstein Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Health Foundation</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHHS-Westlake Medical Center</name>
      <address>
        <city>Westlake</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ECOG-ACRIN Cancer Research Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Breast Center at One Hundred Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farmington Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Utah</state>
        <zip>84025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Jordan Health Center</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Martha Jefferson Hospital</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Leigh Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ThedaCare Regional Cancer Center</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Medical Center</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProHealth D N Greenwald Center</name>
      <address>
        <city>Mukwonago</city>
        <state>Wisconsin</state>
        <zip>53149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProHealth Oconomowoc Memorial Hospital</name>
      <address>
        <city>Oconomowoc</city>
        <state>Wisconsin</state>
        <zip>53066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProHealth Waukesha Memorial Hospital</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UW Cancer Center at ProHealth Care</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rwth Klinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/32096852/</url>
    <description>Primary Manuscript</description>
  </link>
  <results_reference>
    <citation>Comstock CE, Gatsonis C, Newstead GM, Snyder BS, Gareen IF, Bergin JT, Rahbar H, Sung JS, Jacobs C, Harvey JA, Nicholson MH, Ward RC, Holt J, Prather A, Miller KD, Schnall MD, Kuhl CK. Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. JAMA. 2020 Feb 25;323(8):746-756. doi: 10.1001/jama.2020.0572. Erratum in: JAMA. 2020 Mar 24;323(12):1194.</citation>
    <PMID>32096852</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <results_first_submitted>October 23, 2020</results_first_submitted>
  <results_first_submitted_qc>January 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2021</results_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>With publication</ipd_time_frame>
    <ipd_url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276668/bin/NIHMS1578579-supplement-Supplement_I.docx</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02933489/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02933489/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women with dense breasts scheduled for routine screening with DBT were enrolled to receive DBT and AB-MR, with scan order determined by randomization. The first subject was accrued on December 27, 2016, and accrual ended on November 10, 2017. A total of 48 institutions participated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A (DBT, AB-MR)</title>
          <description>Participants undergo DBT followed by AB-MR, for under 10 minutes, on the same day or within 24 hours at baseline and then after 1 year.&#xD;
AB-MR: Contrast-enhanced Abbreviated Magnetic Resonance Imaging (MRI) DBT: Digital Tomosynthesis Mammography</description>
        </group>
        <group group_id="P2">
          <title>Arm B (AB-MR, DBT)</title>
          <description>Participants undergo AB-MR, for under 10 minutes, followed by DBT on the same day or within 24 hours at baseline and then after 1 year.&#xD;
AB-MR: Contrast-enhanced Abbreviated Magnetic Resonance Imaging (MRI) DBT: Digital Tomosynthesis Mammography</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="757"/>
                <participants group_id="P2" count="759"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>DBTperformed</title>
              <participants_list>
                <participants group_id="P1" count="726"/>
                <participants group_id="P2" count="737"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>AB MR Performed</title>
              <participants_list>
                <participants group_id="P1" count="713"/>
                <participants group_id="P2" count="733"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="713"/>
                <participants group_id="P2" count="731"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to complete exams (other)</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A (DBT, AB-MR)</title>
          <description>Participants undergo DBT followed by AB-MR, for under 10 minutes, on the same day or within 24 hours at baseline and then after 1 year.&#xD;
AB-MR: Contrast-enhanced Abbreviated Magnetic Resonance Imaging (MRI) DBT: Digital Tomosynthesis Mammography</description>
        </group>
        <group group_id="B2">
          <title>Arm B (AB-MR, DBT)</title>
          <description>Participants undergo AB-MR, for under 10 minutes, followed by DBT on the same day or within 24 hours at baseline and then after 1 year.&#xD;
AB-MR: Contrast-enhanced Abbreviated Magnetic Resonance Imaging (MRI) DBT: Digital Tomosynthesis Mammography</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="757"/>
            <count group_id="B2" value="759"/>
            <count group_id="B3" value="1516"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="8.7"/>
                    <measurement group_id="B2" value="54.9" spread="8.4"/>
                    <measurement group_id="B3" value="54.9" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="757"/>
                    <measurement group_id="B2" value="759"/>
                    <measurement group_id="B3" value="1516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="704"/>
                    <measurement group_id="B2" value="678"/>
                    <measurement group_id="B3" value="1382"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="648"/>
                    <measurement group_id="B2" value="639"/>
                    <measurement group_id="B3" value="1287"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Pre-menopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="442"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Peri-menopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Naturally post-menopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="316"/>
                    <measurement group_id="B2" value="355"/>
                    <measurement group_id="B3" value="671"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Surgically post-menopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown (data not available)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Breast density (baseline DBT)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Almost entirely fat</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Scattered fibroglandular densities</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Heterogeneously dense</title>
                  <measurement_list>
                    <measurement group_id="B1" value="564"/>
                    <measurement group_id="B2" value="564"/>
                    <measurement group_id="B3" value="1128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extremely dense</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="222"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Scan not performed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior personal history of breast cancer</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="724"/>
                    <measurement group_id="B2" value="728"/>
                    <measurement group_id="B3" value="1452"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Screen-detected Invasive Cancer Verified by Pathology</title>
        <description>For each modality, the detection rate of invasive cancers is defined as the proportion of participants who had an invasive cancer detected by the modality at baseline and verified by pathology versus the total number of participants. In the out come measures table below, these proportions will be automatically calculated, multiplied by 100, and be presented as percentages (%).</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Subjects with both DBT and AB-MR</population>
        <group_list>
          <group group_id="O1">
            <title>Digital Breast Tomosynthesis (DBT)</title>
            <description>Detection of Cancer based on results of Digital Breast Tomosynthesis (DBT) performed within 30 days following registration.&#xD;
DBT and abbreviated -MR were performed on the same day and interpreted by two different radiologists, each blinded to the other modality. However, DBT and AB-MR were allowed to be performed within 24 hours of each other, as long as the radiologists remained blinded to the results of the other modality</description>
          </group>
          <group group_id="O2">
            <title>Abbreviated Breast MR (AB-MR)</title>
            <description>Detection of Cancer based on results of abbreviated breast MR (AB-MR) performed within 30 days following registration.&#xD;
DBT and AB-MR were performed on the same day and interpreted by two different radiologists, each blinded to the other modality. However, DBT and AB-MR were allowed to be performed within 24 hours of each other, as long as the radiologists remained blinded to the results of the other modality</description>
          </group>
        </group_list>
        <measure>
          <title>Screen-detected Invasive Cancer Verified by Pathology</title>
          <description>For each modality, the detection rate of invasive cancers is defined as the proportion of participants who had an invasive cancer detected by the modality at baseline and verified by pathology versus the total number of participants. In the out come measures table below, these proportions will be automatically calculated, multiplied by 100, and be presented as percentages (%).</description>
          <population>Subjects with both DBT and AB-MR</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1444"/>
                <count group_id="O2" value="1444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No Invasive Cancer Detected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1437"/>
                    <measurement group_id="O2" value="1427"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Invasive Cancer Detected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The proportion of participants who had an invasive cancer, verified by pathology, detected by each modality (the invasive cancer detection rates) will be made using exact McNemar's test.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0: DBT = AB-MR</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>McNemar</method>
            <param_type>Wald interval with Bonett-Price Laplace</param_type>
            <param_value>0.007</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0022</ci_lower_limit>
            <ci_upper_limit>0.0116</ci_upper_limit>
            <estimate_desc>Wald interval with Bonett-Price Laplace, described in :&#xD;
Fagerland MW, Lydersen S, Laake P. Recommended tests and confidence intervals for paired binomial proportions. Statist. Med. 2014; 33:2850-75.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prediction of Breast Cancer (Sensitivity and Specificity)</title>
        <description>Reference standard positive (RS+): breast cancer (invasive or DCIS) detected on the year 0 screening or reported at any time from the year 0 to the year 1 screening.&#xD;
Reference standard negative (RS-): No breast cancer reported at any time from the year 0 to the year 1 screen.&#xD;
Incomplete: No Year 1 imaging, and &lt;11 months of patient follow-up (&lt;330 days) after year 0 screen&#xD;
Positive Test (T+) is defined as the imaging modality result is positive (BI-RADS 3-5), and the location of the finding is matches the location of the cancer indicated by the reference standard.&#xD;
Negative Test (T-) will be estimated as the fraction of reference standard negative subjects for whom the imaging modality result was negative (BI-RADS 1-2).&#xD;
95% confidence intervals for the sensitivity and specificity of each modality calculated using the Wilson method.</description>
        <time_frame>Baseline to up to 1 year</time_frame>
        <population>of the 1444 women available for analysis 14 were missing reference standard information.</population>
        <group_list>
          <group group_id="O1">
            <title>Test A: Digital Breast Tomography</title>
            <description>Results of the Digital Breast Tomography (DBT) interpretation</description>
          </group>
          <group group_id="O2">
            <title>Test B: Abbreviated MR</title>
            <description>Results of the Abbreviated MR interpretation</description>
          </group>
        </group_list>
        <measure>
          <title>Prediction of Breast Cancer (Sensitivity and Specificity)</title>
          <description>Reference standard positive (RS+): breast cancer (invasive or DCIS) detected on the year 0 screening or reported at any time from the year 0 to the year 1 screening.&#xD;
Reference standard negative (RS-): No breast cancer reported at any time from the year 0 to the year 1 screen.&#xD;
Incomplete: No Year 1 imaging, and &lt;11 months of patient follow-up (&lt;330 days) after year 0 screen&#xD;
Positive Test (T+) is defined as the imaging modality result is positive (BI-RADS 3-5), and the location of the finding is matches the location of the cancer indicated by the reference standard.&#xD;
Negative Test (T-) will be estimated as the fraction of reference standard negative subjects for whom the imaging modality result was negative (BI-RADS 1-2).&#xD;
95% confidence intervals for the sensitivity and specificity of each modality calculated using the Wilson method.</description>
          <population>of the 1444 women available for analysis 14 were missing reference standard information.</population>
          <units>percentage of correct classifications</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity (T+|RS+)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="22.2" upper_limit="59.2"/>
                    <measurement group_id="O2" value="95.7" lower_limit="79.0" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity (T-|RS-)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="1407"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="96.5" upper_limit="98.1"/>
                    <measurement group_id="O2" value="86.7" lower_limit="84.8" upper_limit="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sensitivity DBT = Sensitivity AB-MR</non_inferiority_desc>
            <p_value>0.001</p_value>
            <p_value_desc>The comparison of the sensitivity of AB-MR and DBT uses a two-sided exact McNemar's test to account for the paired design 5 secondary comparisons were planned: alpha level of 0.05/5 = 0.01 for p-value significance</p_value_desc>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Specificity DBT = Specificity AB-MR</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The comparison of the Specificity of AB-MR and DBT uses a two-sided exact McNemar's test to account for the paired design 5 secondary comparisons were planned: alpha level of 0.05/5 = 0.01 for p-value significance</p_value_desc>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Predictive Value (PPV) of Biopsies</title>
        <description>Test Positive (T+): Biopsy recommended by imaging, defined as patients with at least one lesion rated BI-RADS 4 or 5 on image interpretation. Reference Standard Positive (RS+): Pathologically confirmed DCIS or invasive disease resultant from a positive test.&#xD;
The 95% confidence interval for PPV of biopsy for each modality were derived from the GEE model using the appropriate estimable contrasts with robust standard errors</description>
        <time_frame>Baseline to up to 1 year</time_frame>
        <population>Positive predictive value is calculated on patients with at least one lesion rated BI-RADS 4 or 5 on image interpretation (I.e., Biopsy recommended) and is the percentage of biopsy recommended by imaging test versus patients with cancer P(D+|T+)</population>
        <group_list>
          <group group_id="O1">
            <title>Biopsy Recommended by Digital Breast Tomography</title>
            <description>Patients with at least one lesion rated BI-RADS 4 or 5 on image interpretation.</description>
          </group>
          <group group_id="O2">
            <title>Biopsy Recommended by AB-MR</title>
            <description>Patients with at least one lesion rated BI-RADS 4 or 5 on Abbreviated MR interpretation.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Predictive Value (PPV) of Biopsies</title>
          <description>Test Positive (T+): Biopsy recommended by imaging, defined as patients with at least one lesion rated BI-RADS 4 or 5 on image interpretation. Reference Standard Positive (RS+): Pathologically confirmed DCIS or invasive disease resultant from a positive test.&#xD;
The 95% confidence interval for PPV of biopsy for each modality were derived from the GEE model using the appropriate estimable contrasts with robust standard errors</description>
          <population>Positive predictive value is calculated on patients with at least one lesion rated BI-RADS 4 or 5 on image interpretation (I.e., Biopsy recommended) and is the percentage of biopsy recommended by imaging test versus patients with cancer P(D+|T+)</population>
          <units>percentage of Biopsy Recommended</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Cases recommended for biopsy by imaging</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1444"/>
                <count group_id="O2" value="1444"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Cases recommended for biopsy by imaging</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="17.0" upper_limit="49.7"/>
                    <measurement group_id="O2" value="19.6" lower_limit="13.2" upper_limit="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Positive Predictive Value (PPV)</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>PPV DBT = PPV AB-MR</non_inferiority_desc>
            <p_value>0.15</p_value>
            <p_value_desc>Generalized estimating equation (GEE) regression with the p-value from the resulting score test.&#xD;
5 secondary comparisons were planned: alpha level of 0.05/5 = 0.01 for p-value significance</p_value_desc>
            <method>Leisenring</method>
            <method_desc>Leisenring W, Alonzo T, Pepe MS. Comparisons of predictive values of binary medical diagnostic tests for paired designs. Biometrics. 2000;56:345-351</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Call Back/Additional Imaging/Short-term Follow Rates for DBT and AB-MR</title>
        <description>For DBT:&#xD;
DBT: Call back is defined as having additional views or targeted ultrasound to evaluate DBT findings DBT: short term follow up (STFU) is defined as having at least one lesion rated BI-RADS 3 on DBT DBT: Additional imaging recommendation is defined as having either call back or STFU&#xD;
For AB-MR:&#xD;
Ab-MR: Call back does not apply to AB-MR and will not be evaluated Ab-MR: Short Term Follow-up (STFU) is defined as having at least one lesion rated BI-RADS 3 on AB-MR Ab-MR: Additional imaging recommendation is defined as having a STFU</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DBT Additional Imaging Recommendation</title>
            <description>subjects requiring further assessment by DBT (i.e. either a call back or short term follow up (STFU)) Call back is defined as having additional views or targeted ultrasound to evaluate DBT findings STFU is defined as having at least one lesion rated BI-RADS 3 on DBT Additional imaging recommendation is defined as having either call back or STFU</description>
          </group>
          <group group_id="O2">
            <title>AB-MR Additional Imaging Recommendation</title>
            <description>subjects requiring further assessment by AB-MR Call back does not apply to AB-MR and will not be evaluated Short Term Follow-up (STFU) is defined as having at least one lesion rated BI-RADS 3 on AB-MR Additional imaging recommendation is defined as having a STFU</description>
          </group>
        </group_list>
        <measure>
          <title>Call Back/Additional Imaging/Short-term Follow Rates for DBT and AB-MR</title>
          <description>For DBT:&#xD;
DBT: Call back is defined as having additional views or targeted ultrasound to evaluate DBT findings DBT: short term follow up (STFU) is defined as having at least one lesion rated BI-RADS 3 on DBT DBT: Additional imaging recommendation is defined as having either call back or STFU&#xD;
For AB-MR:&#xD;
Ab-MR: Call back does not apply to AB-MR and will not be evaluated Ab-MR: Short Term Follow-up (STFU) is defined as having at least one lesion rated BI-RADS 3 on AB-MR Ab-MR: Additional imaging recommendation is defined as having a STFU</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1444"/>
                <count group_id="O2" value="1444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Call back</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="NA">For AB-MR, the definition of call back does not apply.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Short-term follow-up (subject-level)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional imaging recommendation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The exact p-value from McNemar's test is reported for for comparing the DBT against the AB-MR short term follow-up rates</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0: DBT short term follow-up rate = AB-MR short term follow-up rate</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>To adjust for multiplicity, using the Bonferroni correction, secondary comparisons are compared against an adjusted alpha level of 0.05/5=0.01 corresponding to the 5 secondary comparisons outlined in the Statistical Analysis Plan (SAP)</p_value_desc>
            <method>McNemar</method>
            <method_desc>exact p-value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The exact p-value from McNemar's test is reported for for comparing the DBT against the AB-MR additional imaging rates</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0: DBT additional imaging rate =AB-MR additional imaging rate</non_inferiority_desc>
            <p_value>0.02</p_value>
            <p_value_desc>To adjust for multiplicity, using the Bonferroni correction, secondary comparisons are compared against an adjusted alpha level of 0.05/5 = 0.01, corresponding to the 5 secondary comparisons outlined in the SAP</p_value_desc>
            <method>McNemar</method>
            <method_desc>exact p-values</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ductal Carcinoma in Situ (DCIS) Detected on Abbreviated Breast-magnetic Resonance (MR) and Digital Tomosynthesis Mammography (DBT)</title>
        <description>The analysis for will be descriptive. If the Oncotype-DCIS score was performed, the distributions of scores will be tabulated and compared.&#xD;
A low risk score is less than 39, and a high risk score is 55 or higher. A score of 39 to 54 is intermediate risk.</description>
        <time_frame>Up to 1 year</time_frame>
        <posting_date>02/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incident Cancer Rate</title>
        <description>Breast cancer incidence will be estimated. Person-years will be measured.</description>
        <time_frame>Up to 3 years</time_frame>
        <posting_date>02/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Biologies of Invasive Cancers</title>
        <description>The analysis for will be descriptive. The frequencies of cancer types determined by the NanoString analysis will be tabulated and compared.</description>
        <time_frame>Up to 1 year</time_frame>
        <posting_date>02/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Factors Associated With Willingness to Return for Screening</title>
        <description>Polytomous logistic regression will be used to examine factors associated with willingness to return, including screen result, cancer status, and demographic characteristics.</description>
        <time_frame>Up to 1 year</time_frame>
        <posting_date>03/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient-reported Short-term Quality of Life Related to Diagnostic Testing</title>
        <description>Separate Testing Morbidities Index (TMI) scores will be computed for abbreviated breast-magnetic resonance (MR) and digital tomosynthesis mammography (DBT) after the baseline screen. Scores will be compared using a nonparametric test that accounts for the pairing of scores by participant.</description>
        <time_frame>Baseline to up to 1 year</time_frame>
        <posting_date>02/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Willingness to Return for Testing With Abbreviated Breast-magnetic Resonance (MR) Versus Digital Tomosynthesis Mammography (DBT)</title>
        <description>The proportions of participants willing to return for screening with either test, AB-MRI only, DBT only, or not willing to return for either test will be estimated.</description>
        <time_frame>Up to 1 year</time_frame>
        <posting_date>03/2023</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year for Adverse Events and All deaths while on-study</time_frame>
      <desc>Serious Adverse Events (SAE), in addition to the standard definition include:&#xD;
All Grade 5 events occurring within 30 days of imaging, regardless of attribution or unexpectedness All Grade 4 events occurring within 30 days of imaging that are unexpected and have an attribution of &quot;Possible, Probable, Definite&quot; All Grade 4 kidney adverse events All occurrences of Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD) All Grade 5 events while on study</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>All participants scheduled for both DBT and AB-MR Note, because of the temporal proximity (generally the same day), it is not possible to attribute the adverse events either by arm or by an individual modality.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v5.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1444"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <description>Death not otherwise specified [NOS] occurring more than 461 days after the year 0 screening intervention.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1444"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <description>Disease progression [Death] This death occurred 395 days after the year 0 screening intervention and after hospital admission for neurosurgery for metastatic disease to the brain.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm of the right lung</sub_title>
                <description>Malignant neoplasm of the right lung [Death] occurring 136 days after the year 0 screening intervention.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <description>Intracranial hemorrhage [Death] occurring 106 days after the year 0 screening intervention.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>Respiratory failure [Death] This death occurred 395 days after the year 0 screening intervention and after hospital admission for neurosurgery for metastatic disease to the brain.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v5.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <description>Vertigo [Mild symptoms]</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral Eye swelling</sub_title>
                <description>Bilateral Eye swelling [Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; no change in vision]</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea [Loss of appetite without alteration in eating habits]</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1444"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Vomiting [3 - 5 episodes (separated by 5 minutes) in 24 hrs]</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Facial rash</sub_title>
                <description>Facial rash [Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated]</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <description>Infusion site extravasation [Painless edema]</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <description>Localized edema [Moderate localized edema and intervention indicated; limiting instrumental ADL]</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Pain [Mild pain]</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>Allergic reaction [Intervention or infusion interruption indicated; responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDS, narcotics); prophylactic medications indicated for &lt;=24 hrs]</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1444"/>
              </event>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>Allergic reaction [Transient flushing or rash, drug fever &lt;38 degrees C (&lt;100.4 degrees F); intervention not indicated]</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <description>Bruising [Localized or in a dependent area]</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <description>Vascular access complication [Device dislodgement, blockage, leak, or malposition; device replacement indicated]</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Back pain [Mild pain]</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <description>Vasovagal reaction [Present]</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Anxiety [Mild symptoms; intervention not indicated]</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <description>Breast pain [Moderate pain; limiting Instrumental activities of daily living (IADL)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <description>Cough [Mild symptoms; nonprescription intervention indicated]</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <description>Flushing [Asymptomatic; clinical or diagnostic observations only; intervention not indicated]</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Hematoma [Mild symptoms; intervention not indicated]</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Hematoma [Minimally invasive evacuation or aspiration indicated]</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1444"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director Clinical Research Administration</name_or_title>
      <organization>ECOG-ACRIN</organization>
      <phone>800-227-5463 ext 4765</phone>
      <email>dhartfeil@acr.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

